Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ubiquitin conjugating enzyme E2 C pseudogene 2 (UBE2CP2) is classified as a pseudogene and does not encode a functional protein product. It is related by sequence homology to the UBE2C gene, which itself encodes an active E2 ubiquitin-conjugating enzyme involved in ubiquitin-mediated protein degradation. However, UBE2CP2 lacks documented expression of a functioning protein and is not known to have a direct biological or disease role, nor is it a therapeutic target. Gene databases and scientific resources do not report any clinically-relevant activity, ligand binding, or disease association for this pseudogene. Therefore, based on public genomic databases and current knowledge, UBE2CP2 is not a valid or actionable drug target, and any references suggesting otherwise are likely due to misclassification or confusion with the functional gene UBE2C.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ubiquitin conjugating enzyme E2 C pseudogene 2 (UBE2CP2).